ApoB 90 mg/dL — why this beats LDL-C as a cardiovascular risk marker
Apolipoprotein B (ApoB) measures the number of atherogenic lipoprotein particles in your bloodstream — every LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB. An ApoB of 90 mg/dL is above the optimal threshold most contemporary cardiovascular research sets (~80 mg/dL), placing you at moderate cardiovascular risk regardless of what your LDL-C number says. ApoB is increasingly considered a better predictor of cardiovascular events than LDL-C because it counts particles, not cholesterol mass — and a person with small dense LDL particles can have a "normal" LDL-C but an elevated ApoB and a high event rate.
Reference ranges
| Optimal (most cardiology research) | < 80 mg/dL |
| Borderline | 80 – 100 mg/dL |
| High | 100 – 130 mg/dL |
| Very high | > 130 mg/dL |
What this marker measures
ApoB is the structural protein on every atherogenic lipoprotein particle. Because each particle carries exactly one ApoB molecule, the ApoB concentration in serum is a direct count of atherogenic particles. This is fundamentally different from LDL-C, which measures the mass of cholesterol carried inside LDL particles — two patients with identical LDL-C can have very different particle counts depending on whether their particles are large and cholesterol-rich (lower count, lower risk) or small and dense (higher count, higher risk). The pivotal INTERHEART study and the UK Biobank lipid analyses found ApoB to be the strongest single lipid predictor of myocardial infarction.
Why might it be elevated?
- ·Familial hypercholesterolaemia or genetic LDL receptor variants
- ·Insulin resistance and metabolic syndrome (raises VLDL/IDL particle production)
- ·High saturated fat intake elevating LDL particle production
- ·Hypothyroidism reducing LDL clearance
- ·Anabolic steroid use suppressing HDL and raising LDL particles
- ·Nephrotic syndrome
Why might it be low?
- ·Aggressive lipid-lowering therapy (statin, PCSK9 inhibitor, ezetimibe)
- ·Hyperthyroidism increasing LDL clearance
- ·Severe malabsorption / chronic illness
- ·Genetic abetalipoproteinaemia (rare)
Compounds whose research literature has investigated this area
These are research-grade compounds in our catalogue whose published study literature touches the same biology. Listed for research context — not as recommendations for self-administration.
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue — pre-reconstituted for researchers running extended protocols.
Tesamorelin is an approved GHRH analogue. The research-grade form is used widely in GH-axis, lipid-metabolism, and hepatic-fat research.
Cagrilintide is a long-acting amylin analogue most widely investigated in combination with semaglutide under the CagriSema programme. Commonly stacked with GLP-1 receptor agonists in preclinical research.
FAQ
Why is ApoB better than LDL-C?+
LDL-C measures cholesterol mass. ApoB counts particles. Particle count is what actually drives atherosclerosis: more particles = more chances for one to penetrate the arterial wall. People with discordance (high LDL-C, low ApoB or vice versa) have outcomes that track ApoB, not LDL-C.
My LDL is normal but ApoB is 90 — should I worry?+
Discordance like this typically indicates small, dense LDL particles — common in insulin resistance and metabolic syndrome. The research literature is consistent: when the two markers disagree, ApoB is the better risk predictor.
Does ApoB respond to lifestyle?+
Yes. Saturated fat reduction, weight loss, and exercise all reduce ApoB in trials, though typically only by 10–20%. Pharmacological reduction (statins, PCSK9 inhibitors) is more aggressive (50–70%) and is what cardiology guidelines reach for above certain thresholds.
References
- Sniderman AD et al. (2019). Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. PMID 31562737
This page describes biomarker research and reference ranges for self-tracking and research-context discussion only. It is not medical advice, not a diagnosis, and not a substitute for a qualified physician. Take any concerns about your health to a clinician.
Have your own panel? Read it next to the standard reference ranges with our free analyse tool.
Analyse my blood work →